- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00858637
Efficacy and Safety Study of MCI-196 Versus Simvastatin for Dyslipidaemia in Chronic Kidney Disease (CKD) Subjects on Dialysis
December 8, 2014 updated by: Mitsubishi Tanabe Pharma Corporation
A Phase III, Multicentre, Double-blind, Double-dummy, Randomised, Flexible-dose, Comparative Study of MCI-196 Versus Simvastatin for the Treatment of Dyslipidaemia in Subjects With Chronic Kidney Disease on Dialysis (Incorporating a Placebo-controlled Withdrawal Phase)
The primary objective of this study is to demonstrate the superiority of MCI-196 over placebo and non-inferiority with simvastatin in reducing serum low-density lipoprotein (LDL)-cholesterol in subjects with chronic kidney disease Stage V on dialysis.
This study incorporates a Washout Period and two treatment periods - an active comparison phase and a placebo-controlled withdrawal phase.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
260
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brest, Belarus
-
Gomel, Belarus
-
Grodno, Belarus
-
Minsk, Belarus
-
Vitebsk, Belarus
-
-
-
-
-
Gabrovo, Bulgaria
-
Plovdiv, Bulgaria
-
Sofia, Bulgaria
-
-
-
-
-
Karlovac, Croatia
-
Osijek, Croatia
-
-
-
-
-
Esbjerg, Denmark
-
Roskilde, Denmark
-
-
-
-
-
Jakarta, Indonesia
-
Malang, Indonesia
-
Medan, Indonesia
-
Palembang, Indonesia
-
Tamanlarea Makassar, Indonesia
-
-
-
-
-
Ashkelon, Israel
-
Nahariya, Israel
-
-
-
-
-
Bellano, Italy
-
Catania, Italy
-
Lecco, Italy
-
Merate, Italy
-
Milano, Italy
-
Oggiono, Italy
-
-
-
-
-
Riga, Latvia
-
Valmiera, Latvia
-
-
-
-
-
Kaunas, Lithuania
-
Kedauniai, Lithuania
-
Vilnius, Lithuania
-
-
-
-
-
Johor, Malaysia
-
Kelantan, Malaysia
-
Penang, Malaysia
-
Perak, Malaysia
-
-
-
-
-
Bucharest, Romania
-
Timisoara, Romania
-
-
-
-
-
Singapore, Singapore
-
-
-
-
-
Bangkok, Thailand
-
Phitsanulok, Thailand
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female, and is >=18 years old
- Stable hemodialysis or peritoneal dialysis
- Subjects undergoing regular dialysis treatment
- If Female and of child-bearing potential, have a negative serum pregnancy test
- Male subjects must agree to use appropriate contraception
Exclusion Criteria:
- Current clinically significant medical comorbidities, which may substantially compromise subject safety, or expose him/her to undue risk, or interfere significantly with study procedures and which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study
- Serum albumin level < 30 g/L
- Triglycerides level > 6.76 mmol/L (600 mg/dL)
- LDL-cholesterol level > 4.94 mmol/L (190 mg/dL)
- A History of significant gastrointestinal motility problems
- Biliary obstruction or proven liver dysfunction
- A positive test for HIV 1 and 2 antibodies
- A history of substance or alcohol abuse within the last year
- The subject has a history of rhabdomyolysis or myopathy
- Schedule to receive a kidney transplant within the next 6 months
- The subject has porphyria
- Participation in a clinical study with any experimental medication in the last 30 days or an experimental biological product within the last 90 days prior to signing of informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 MCI-196
|
Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Other Names:
Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
|
Placebo Comparator: 2 Placebo of MCI-196
|
Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
|
Active Comparator: 3 Simvastatin
|
Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
|
Placebo Comparator: 4 Placebo of Simvastatin
|
Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Serum LDL-cholesterol Levels From Week 16 to Week 20 (LOCF) (ITT2)
Time Frame: week20 minus week16
|
Percent Change from Week 16 to Week 20 (LOCF)
|
week20 minus week16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change in Serum LDL-cholesterol Levels From Baseline to Week 16 (LOCF) (ITT1)
Time Frame: week16 minus week0
|
Percent Change from Baseline to Week 16 (LOCF)
|
week16 minus week0
|
Change in Phosphorus(P), Calcium(Ca), Calcium-phosphorus Ion Product(PxCa) and Parathyroid Hormone (PTH)
Time Frame: 16 weeks and 20 weeks
|
16 weeks and 20 weeks
|
|
Vital Signs, Adverse Events, and Laboratory Values
Time Frame: throughout study
|
throughout study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
March 9, 2009
First Submitted That Met QC Criteria
March 9, 2009
First Posted (Estimate)
March 10, 2009
Study Record Updates
Last Update Posted (Estimate)
December 30, 2014
Last Update Submitted That Met QC Criteria
December 8, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Urologic Diseases
- Renal Insufficiency
- Lipid Metabolism Disorders
- Kidney Diseases
- Renal Insufficiency, Chronic
- Dyslipidemias
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Gastrointestinal Agents
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Simvastatin
- Bile Acids and Salts
Other Study ID Numbers
- MCI-196-E11
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Centre Hospitalier Saint Joseph Saint Luc de LyonNot yet recruitingKidney Failure, Chronic | Diet Habit | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Chronic Kidney Disease, Stage 3 (Moderate) | Chronic Kidney Disease Stage 3A (Disorder)France
-
A.C. AbrahamsCompletedEnd Stage Renal Disease | Chronic Kidney Disease | End Stage Kidney Disease | Chronic Kidney FailureNetherlands
-
Far Eastern Memorial HospitalActive, not recruitingMetabolic Syndrome | Chronic Disease | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
Clinical Trials on MCI-196
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | Hyperphosphatemia | DialysisUnited States, Puerto Rico
-
Mitsubishi Tanabe Pharma CorporationTerminatedChronic Kidney Disease | Hyperphosphatemia | DialysisFrance, Poland, Spain, Serbia, South Africa, Czech Republic, Germany, Macedonia, The Former Yugoslav Republic of, Italy, United Kingdom
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | Hyperphosphatemia | DialysisUnited States, Canada
-
Mitsubishi Tanabe Pharma CorporationCompletedDyslipidemia | Chronic Kidney Disease | Hyperphosphatemia | DialysisPoland, Ukraine, Serbia, Russian Federation, Hungary, Malaysia, Italy, Macedonia, The Former Yugoslav Republic of
-
Northwestern UniversityNational Institutes of Health (NIH); Shirley Ryan AbilityLabRecruitingStroke | Stroke, AcuteUnited States
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | HyperphosphatemiaFrance, Poland, United Kingdom, Spain, South Africa, Australia, Czech Republic, Germany, Hungary, Italy, Austria
-
Mitsubishi Tanabe Pharma CorporationCompletedChronic Kidney Disease | Hyperphosphatemia | DialysisFrance, Poland, Ukraine, United Kingdom, Spain, Serbia, South Africa, Russian Federation, Czech Republic, Germany, Hungary, Italy, Austria, Macedonia, The Former Yugoslav Republic of, Malaysia
-
University of PittsburghNational Institute of Mental Health (NIMH)Completed
-
Assistance Publique Hopitaux De MarseilleRecruiting